News

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...
The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times ...
It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...
Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...
AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.
The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer.
OPEN The FTSE 100 was expected to open 19.9 points lower on Friday after wrapping up the previous session 0.55% higher at 8,823.20.
American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a ...